Recruiting
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
ClinicalTrials.gov IDNCT06933836
PhaseNot Applicable
Enrollment55
SponsorBarnet Dulaney Perkins Eye Centers
Age30 Years
SexALL
Conditions studied
Open Angle Glaucoma (OAG)
About this study
DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
Interventions
- Device: DSLT enables newly diagnosed patients to remain well controlled and off medications — DSLT enables newly diagnosed patients to remain well controlled and off medications
Primary outcomes
- Success of IOP Reduction Through DSLT Utilization (12 months)
Eligibility information
Inclusion Criteria:
* Primary open angle glaucoma
* Patients age 30 or greater with an IOP of 18-26 mmHg
* Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines)
* DSLT procedure
Exclusion Criteria:
* History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery
* Angle closure patients
* Ocular Hypertension
* Baseline VF MD of worse than -12dB
* Uncontrolled systemic microvascular disease (eg. HTN, DM)
* Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium, significant senile arcus and pterygium)
Study locations
- Barnet Dulaney Perkins Eye Centers, Mesa, Arizona 85206 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.